サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1535259

緑内障治療薬市場：規模・予測、世界と地域シェア、動向、成長機会分析レポート：薬剤クラス別、適応症別、流通チャネル別、地域別

Glaucoma Therapeutics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Indication, Distribution Channel, and Geography

出版日
ページ情報
英文 150 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
緑内障治療薬市場：規模・予測、世界と地域シェア、動向、成長機会分析レポート：薬剤クラス別、適応症別、流通チャネル別、地域別
出版日: 2024年07月15日
発行: The Insight Partners
ページ情報: 英文 150 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

緑内障治療薬市場は、2023年に62億4,000万米ドルと評価され、2031年には80億2,000万米ドルに達すると予測され、2023～2031年のCAGRは3.2％と推定されます。

市場成長を促進する主な要因は、緑内障の有病率の増加、緑内障に対する意識の高まりと早期診断、製品上市の増加が市場成長を促進すると予想されることです。しかし、投薬計画の遵守の問題や治療費の高さが、緑内障治療薬市場の成長の妨げとなっています。

緑内障治療薬市場の動向：

緑内障と呼ばれる眼疾患は、主に加齢による眼圧の上昇に伴って視神経が徐々に障害され、最終的には不可逆的な失明に至る可能性があります。緑内障の最も一般的な治療のひとつは、点眼薬を使って眼圧を下げることです。しかし、患者の点眼に対するアドヒアランスは難しく、不十分な患者教育が治療の成功を妨げることもあります。さらに、眼圧降下薬は局所的・全身的な副作用を引き起こす可能性があり、治療をさらに複雑にします。安定性の向上、循環時間の延長、標的結合特性などを備えた改良型製剤の市場開拓に注目が集まっており、新規製品が市場に加わる可能性が高いです。緑内障治療薬における最近の進歩は、市場で利用可能な治療に革命をもたらしています。適切な構造と優れた結合能力を持つナノ粒子の使用は、薬剤のバイオアベイラビリティと有効性を促進します。徐放性（SR）インプラントやその他の革新的なドラッグデリバリーシステムは、従来の点眼薬に比べて患者のコンプライアンスを改善し、副作用を軽減します。POAG治療の障壁を克服できる可能性があるため、複数の企業が局所投与に代わるSRドラッグデリバリーシステムを開発しています。2022年にPubMed Centralに掲載された論文によると、FDA（米国食品医薬品局）がPOAGに対して承認した唯一のSR療法は、アラガン社のビマトプロストSR（DurystaTM）です。ビマトプロスト眼リング（Allergan）、iDose（Glaukos Corporation）、ENV515（Envisia Therapeutics）、OTX-TP（Ocular Therapeutix）、OTX-TIC（Ocular Therapeutix）、ラタノプロスト遊離酸SR（PolyActiva）を含む他のSR療法は現在研究中です。POAG管理におけるSRドラッグデリバリー技術は、治療パラダイムを転換し、治療成績を劇的に改善する可能性があります。したがって、新規ドラッグデリバリー手法と併用療法の開拓は、緑内障治療薬市場の主要な動向であり続けると思われます。

緑内障治療薬市場セグメント別概要

緑内障治療薬市場は、薬剤クラス別、適応症別、流通チャネル別に区分されます。

薬剤クラス別では、市場はβ遮断薬、αアドレナリン作動薬、プロスタグランジンアナログ、炭酸脱水酵素阻害薬、併用薬、その他に分けられます。2023年には、プロスタグランジンアナログセグメントがより大きな市場シェアを占めています。プロスタグランジンアナログは、緑内障患者の高眼圧に対する第一選択の治療薬です。プロスタグランジンアナログは1日1回の投与で眼圧を大幅に低下させ、全身的な副作用も少ないです。したがって、プロスタグランジンアナログの利点が緑内障治療薬市場規模の拡大の原因となっています。

市場は適応症別に、開放隅角緑内障、閉塞隅角緑内障、その他に区分されます。開放隅角緑内障セグメントは、2023年に最大の緑内障治療薬市場シェアを占め、2023年から2031年にかけて最も高いCAGRを記録すると予測されています。開放隅角緑内障は、緑内障の最も一般的な形態であり、個人の約95％が罹患しています。最初は何の症状も現れないです。しかし、ある時点で、治療せずに側方（周辺）視野を失い始め、全盲になることもあります。

市場は流通チャネル別に、病院薬局、小売薬局、オンライン薬局に区分されます。2023年は病院薬局セグメントが市場を独占しています。

緑内障治療薬市場地理的概観

緑内障治療薬市場の調査範囲は、北米（米国、カナダ、メキシコ）、欧州（スペイン、英国、ドイツ、フランス、イタリア、その他欧州地域）、アジア太平洋（韓国、中国、インド、日本、オーストラリア、その他アジア太平洋地域）、中東・アフリカ（南アフリカ、サウジアラビア、アラブ首長国連邦、その他中東・アフリカ地域）、中南米（ブラジル、アルゼンチン、その他中南米地域）です。アジア太平洋地域は、2023年から2031年にかけて最も速いCAGRを記録すると予想されています。アジア太平洋地域の緑内障治療薬市場の成長には、新規緑内障治療薬開発のための進行中の臨床研究や、同地域におけるヘルスケア支出の増加などの要因が寄与しています。売上高では、北米が2023年に最大の緑内障治療薬市場シェアを占めました。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 2次調査
  • 1次調査
    • 仮説の策定
    • マクロ経済要因分析
    • 基礎数値の作成
    • データの三角測量
    • 国レベルのデータ

第4章 緑内障治療薬の市場情勢

  • PEST分析

第5章 緑内障治療薬市場-主要市場力学

  • 緑内障治療薬市場- 主要市場力学
  • 市場促進要因
    • 緑内障罹患率の増加
    • 製品上市、提携、買収の増加
  • 市場抑制要因
    • 服薬コンプライアンスの問題
  • 市場機会
    • ウェアラブル技術の開発
  • 今後の動向
    • 新しいドラッグデリバリー方法の開発
  • 促進要因と抑制要因の影響

第6章 緑内障治療薬市場：世界市場分析

  • 緑内障治療薬市場の収益、2021年～2031年
  • 緑内障治療薬市場の予測分析

第7章 緑内障治療薬市場分析-薬剤クラス別

  • β遮断薬
  • αアドレナリン作動薬
  • プロスタグランジン類縁体
  • 炭酸脱水酵素阻害薬
  • 併用薬
  • その他

第8章 緑内障治療薬市場の分析-適応症別

  • 開放隅角緑内障
  • 閉塞隅角緑内障
  • その他

第9章 緑内障治療薬市場分析-流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 緑内障治療薬市場- 地域分析

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • アジア太平洋地域のその他諸国
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • その他中東とアフリカ
  • 中南米
    • ブラジル
    • アルゼンチン
    • その他中南米

第11章 緑内障治療薬市場- 業界情勢

  • 緑内障治療薬市場の成長戦略
  • 有機的成長戦略
  • 無機的成長戦略

第12章 企業プロファイル

  • Alcon AG
  • AbbVie Inc
  • Bausch & Lomb Inc
  • Fera Pharmaceuticals, LLC
  • Viatris Inc
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Thea Pharma Inc
  • Santen Pharmaceutical Co., Ltd.

第13章 付録

図表

List Of Tables

  • Table 1. Glaucoma Therapeutics Market Segmentation
  • Table 2. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 3. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 4. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 5. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 6. North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 7. North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 8. North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 9. North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 10. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 11. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 12. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 13. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 14. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 15. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 16. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 17. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 18. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 19. Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 20. Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 21. Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 22. Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 23. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 24. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 25. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 26. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 27. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 28. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 29. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 30. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 31. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 32. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 33. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 34. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 35. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 36. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 37. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 38. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 39. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 40. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 41. Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 42. Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 43. Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 44. Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 45. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 46. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 47. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 48. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 49. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 50. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 51. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 52. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 53. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 54. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 55. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 56. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 57. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 58. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 59. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 60. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 61. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 62. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 63. Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 64. Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 65. Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 66. Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 67. Saudi Arabia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 68. Saudi Arabia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 69. Saudi Arabia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 70. South Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 71. South Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 72. South Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 73. United Arab Emirates: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 74. United Arab Emirates: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 75. United Arab Emirates: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 76. Rest of Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 77. Rest of Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 78. Rest of Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 79. South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 80. South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 81. South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 82. South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 83. Brazil: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 84. Brazil: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 85. Brazil: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 86. Argentina: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 87. Argentina: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 88. Argentina: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 89. Rest of South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 90. Rest of South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 91. Rest of South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 92. Recent Organic Growth Strategies in Glaucoma Therapeutics Market
  • Table 93. Recent Inorganic Growth Strategies in the Glaucoma Therapeutics Market
  • Table 94. Glossary of Terms, Transiaent Protein Expression Market

List Of Figures

  • Figure 1. Glaucoma Therapeutics Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • Figure 5. Glaucoma Therapeutics Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 6. Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Glaucoma Therapeutics Market Share (%) - by Indication (2023 and 2031)
  • Figure 13. Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Glaucoma Therapeutics Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 17. Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Glaucoma Therapeutics Market Breakdown by Region, 2023 and 2031 (%)
  • Figure 21. North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 22. North America: Glaucoma Therapeutics Market Breakdown, by Drug Class (2023 and 2031)
  • Figure 23. North America: Glaucoma Therapeutics Market Breakdown, by Indication (2023 and 2031)
  • Figure 24. North America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 25. North America: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 26. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 27. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 28. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 29. Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 30. Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class (2023 and 2031)
  • Figure 31. Europe: Glaucoma Therapeutics Market Breakdown, by Indication (2023 and 2031)
  • Figure 32. Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 33. Europe: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 34. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 35. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 36. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 37. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 38. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 39. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 40. Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 41. Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Drug Class (2023 and 2031)
  • Figure 42. Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Indication (2023 and 2031)
  • Figure 43. Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 44. Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 45. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 46. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 47. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 48. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 49. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 50. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 51. Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 52. Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class (2023 and 2031)
  • Figure 53. Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Indication (2023 and 2031)
  • Figure 54. Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 55. Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 56. Saudi Arabia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 57. South Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 58. United Arab Emirates: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 59. Rest of Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 60. South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 61. South and Central America: Glaucoma Therapeutics Market Breakdown, by Drug Class (2023 and 2031)
  • Figure 62. South and Central America: Glaucoma Therapeutics Market Breakdown, by Indication (2023 and 2031)
  • Figure 63. South and Central America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 64. South and Central America: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 65. Brazil: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 66. Argentina: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 67. Rest of South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 68. Growth Strategies in Glaucoma Therapeutics Market
目次
Product Code: TIPRE00018828

The glaucoma therapeutics market was valued at US$ 6.24 billion in 2023 and is expected to reach US$ 8.02 billion by 2031; it is estimated to record a CAGR of 3.2% during 2023-2031.

Key factors driving the market growth are the growing prevalence of glaucoma, rising awareness and early diagnosis of the disease, and increasing product launches are expected to drive the market growth. However, compliance issues with medication regimens and the high cost of treatments hinder the glaucoma therapeutics market growth.

Market Trends of the Glaucoma Therapeutics Market:

The gradual damage of the optic nerve-typically associated with high pressure inside the eye (intraocular pressure)-predominantly due to aging can lead to a group of eye diseases called Glaucoma, which can eventually result in irreversible blindness. One of the most common treatments for glaucoma is to reduce intraocular pressure by using eye drops. However, patient adherence to these eye drops can be challenging, and inadequate patient education can impede treatment success. Additionally, ocular hypotensive drugs can cause local and systemic side effects that may further complicate the treatment. Rising focus on the development of improved formulations with enhanced stability, longer circulation times, and targeted binding properties is likely to add novel products to the market. Recent advancements in glaucoma therapeutics have revolutionized the available treatments in the market. The use of nanoparticles with suitable structures and superior binding capabilities facilitates the bioavailability and efficacy of the drug. Sustained-release (SR) implants and other innovative drug delivery systems offer improved patient compliance and reduced side effects compared to conventional eye drops. Several companies are developing SR drug delivery systems as an alternative to topical delivery to potentially overcome barriers in treating POAG. As per the article published in PubMed Central in 2022, the only approved SR therapy for POAG by the Food and Drug Administration (FDA) is Bimatoprost SR (DurystaTM) from Allergan plc. Other SR therapies including bimatoprost ocular ring (Allergan), iDose (Glaukos Corporation), ENV515 (Envisia Therapeutics), OTX-TP (Ocular Therapeutix), OTX-TIC (Ocular Therapeutix), and latanoprost free acid SR (PolyActiva) are under investigation. SR drug delivery technology in POAG management may shift treatment paradigms and dramatically improve outcomes. Therefore, the development of novel drug delivery methods and combination therapies is likely to remain a key trend in the glaucoma therapeutics market.

Glaucoma therapeutics Market: Segmental Overview

The glaucoma therapeutics market is segmented on the basis of drug class, indication, and distribution channel.

By drug class, the market is divided into beta blockers, alpha-adrenergic agonists, prostaglandin analogs, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandin analogs segment held a larger market share in 2023. Prostaglandin analogs are the first-line treatment for high intraocular pressure in glaucoma patients. They offer a once-a-day dosing, a significant reduction in intraocular pressure, and low systemic side effects. Thus, the benefits of prostaglandin analogs are responsible for the expansion of the glaucoma therapeutics market size.

The market, by indication, is segmented into open angle glaucoma, angle closure glaucoma, and others. The open-angle glaucoma segment held the largest glaucoma therapeutics market share in 2023 and is projected to register the highest CAGR from 2023 to 2031. Open-angle glaucoma is the most common form of glaucoma, which affects approximately 95% of individuals. Initially, it does not show any symptoms. However, at some point, an individual may start losing their side (peripheral) vision without treatment, resulting in total blindness.

By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2023.

Glaucoma therapeutics Market: Geographical Overview

The scope of the glaucoma therapeutics market report entails North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). Asia Pacific is expected to register the fastest CAGR in the market from 2023 to 2031. Factors such as ongoing clinical studies for developing novel glaucoma therapies, as well as increasing healthcare expenditures in the region, contribute to the glaucoma therapeutics market growth in Asia Pacific. In terms of revenue, North America accounted for the largest glaucoma therapeutics market share in 2023.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Glaucoma Therapeutics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Glaucoma Therapeutics Market - Key Market Dynamics

  • 5.1 Glaucoma Therapeutics Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Mounting Incidence of Glaucoma Disease
    • 5.2.2 Increasing Number of Product Launches, Collaborations, Acquisitions
  • 5.3 Market Restraints
    • 5.3.1 Medication Regimen Compliance Issues
  • 5.4 Market Opportunities
    • 5.4.1 Development of Wearable Technologies
  • 5.5 Future Trends
    • 5.5.1 Development of Novel Drug Delivery Methods
  • 5.6 Impact of Drivers and Restraints:

6. Glaucoma Therapeutics Market - Global Market Analysis

  • 6.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • 6.2 Glaucoma Therapeutics Market Forecast Analysis

7. Glaucoma Therapeutics Market Analysis - by Drug Class

  • 7.1 Beta Blockers
    • 7.1.1 Overview
    • 7.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Alpha Adrenergic Agonists
    • 7.2.1 Overview
    • 7.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Prostaglandins Analogues
    • 7.3.1 Overview
    • 7.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Carbonic Anhydrase Inhibitors
    • 7.4.1 Overview
    • 7.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Combination Drugs
    • 7.5.1 Overview
    • 7.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

8. Glaucoma Therapeutics Market Analysis - by Indication

  • 8.1 Open Angle Glaucoma
    • 8.1.1 Overview
    • 8.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Angle Closure Glaucoma
    • 8.2.1 Overview
    • 8.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Others
    • 8.3.1 Overview
    • 8.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

9. Glaucoma Therapeutics Market Analysis - by Distribution Channel

  • 9.1 Hospital Pharmacy
    • 9.1.1 Overview
    • 9.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Retail Pharmacy
    • 9.2.1 Overview
    • 9.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Online Pharmacy
    • 9.3.1 Overview
    • 9.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

10. Glaucoma Therapeutics Market - Geographical Analysis

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 North America Glaucoma Therapeutics Market Overview
    • 10.2.2 North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    • 10.2.3 North America: Glaucoma Therapeutics Market Breakdown, by Drug Class
      • 10.2.3.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
    • 10.2.4 North America: Glaucoma Therapeutics Market Breakdown, by Indication
      • 10.2.4.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
    • 10.2.5 North America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.2.5.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 10.2.6 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.2.6.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.2.6.2 United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.2.6.2.1 United States: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.2.6.2.2 United States: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.2.6.2.3 United States: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.2.6.3 Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.2.6.3.1 Canada: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.2.6.3.2 Canada: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.2.6.3.3 Canada: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.2.6.4 Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.2.6.4.1 Mexico: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.2.6.4.2 Mexico: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.2.6.4.3 Mexico: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  • 10.3 Europe
    • 10.3.1 Europe Glaucoma Therapeutics Market Overview
    • 10.3.2 Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    • 10.3.3 Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
      • 10.3.3.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
    • 10.3.4 Europe: Glaucoma Therapeutics Market Breakdown, by Indication
      • 10.3.4.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
    • 10.3.5 Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.3.5.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 10.3.6 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.3.6.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.3.6.2 Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.6.2.1 Germany: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.3.6.2.2 Germany: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.3.6.2.3 Germany: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.3.6.3 France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.6.3.1 France: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.3.6.3.2 France: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.3.6.3.3 France: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.3.6.4 United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.6.4.1 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.3.6.4.2 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.3.6.4.3 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.3.6.5 Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.6.5.1 Italy: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.3.6.5.2 Italy: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.3.6.5.3 Italy: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.3.6.6 Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.6.6.1 Spain: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.3.6.6.2 Spain: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.3.6.6.3 Spain: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.3.6.7 Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.6.7.1 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.3.6.7.2 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.3.6.7.3 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  • 10.4 Asia Pacific
    • 10.4.1 Asia Pacific Glaucoma Therapeutics Market Overview
    • 10.4.2 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    • 10.4.3 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Drug Class
      • 10.4.3.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
    • 10.4.4 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Indication
      • 10.4.4.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
    • 10.4.5 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.4.5.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 10.4.6 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.4.6.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.4.6.2 China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.6.2.1 China: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.4.6.2.2 China: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.4.6.2.3 China: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.4.6.3 Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.6.3.1 Japan: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.4.6.3.2 Japan: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.4.6.3.3 Japan: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.4.6.4 India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.6.4.1 India: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.4.6.4.2 India: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.4.6.4.3 India: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.4.6.5 Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.6.5.1 Australia: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.4.6.5.2 Australia: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.4.6.5.3 Australia: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.4.6.6 South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.6.6.1 South Korea: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.4.6.6.2 South Korea: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.4.6.6.3 South Korea: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.4.6.7 Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.6.7.1 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.4.6.7.2 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.4.6.7.3 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  • 10.5 Middle East and Africa
    • 10.5.1 Middle East and Africa Glaucoma Therapeutics Market Overview
    • 10.5.2 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    • 10.5.3 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
      • 10.5.3.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
    • 10.5.4 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Indication
      • 10.5.4.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
    • 10.5.5 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.5.5.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 10.5.6 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.5.6.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.5.6.2 Saudi Arabia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.5.6.2.1 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.5.6.2.2 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.5.6.2.3 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.5.6.3 South Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.5.6.3.1 South Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.5.6.3.2 South Africa: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.5.6.3.3 South Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.5.6.4 United Arab Emirates: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.5.6.4.1 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.5.6.4.2 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.5.6.4.3 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.5.6.5 Rest of Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.5.6.5.1 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.5.6.5.2 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.5.6.5.3 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  • 10.6 South and Central America
    • 10.6.1 South and Central America Glaucoma Therapeutics Market Overview
    • 10.6.2 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    • 10.6.3 South and Central America: Glaucoma Therapeutics Market Breakdown, by Drug Class
      • 10.6.3.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
    • 10.6.4 South and Central America: Glaucoma Therapeutics Market Breakdown, by Indication
      • 10.6.4.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
    • 10.6.5 South and Central America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.6.5.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 10.6.6 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.6.6.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.6.6.2 Brazil: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.6.6.2.1 Brazil: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.6.6.2.2 Brazil: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.6.6.2.3 Brazil: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.6.6.3 Argentina: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.6.6.3.1 Argentina: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.6.6.3.2 Argentina: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.6.6.3.3 Argentina: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.6.6.4 Rest of South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.6.6.4.1 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.6.6.4.2 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.6.6.4.3 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel

11. Glaucoma Therapeutics Market - Industry Landscape

  • 11.1 Growth Strategies in Glaucoma Therapeutics Market
  • 11.2 Organic Growth Strategies
    • 11.2.1 Overview
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview

12. Company Profiles

  • 12.1 Alcon AG
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 AbbVie Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Bausch & Lomb Inc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Fera Pharmaceuticals, LLC
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Viatris Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Novartis AG
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Sun Pharmaceutical Industries Ltd
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Teva Pharmaceutical Industries Ltd
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Thea Pharma Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Santen Pharmaceutical Co., Ltd.
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms